ICD-10 Coding for Metastatic Adenocarcinoma(C18.7, C22.0, C22.0U)
Explore detailed ICD-10 coding guidelines for metastatic adenocarcinoma, including primary and secondary site documentation, common pitfalls, and billing considerations.
Complete code families applicable to Metastatic Adenocarcinoma
Compare key differences between these codes to ensure accurate selection
| Code | Description | When to Use | Key Documentation |
|---|---|---|---|
| C79.51 | Secondary malignant neoplasm of bone | Use when bone is a secondary site of metastasis. |
|
| C78.7 | Secondary malignant neoplasm of liver and intrahepatic bile duct | Use when liver is a secondary site of metastasis. |
|
Clinical Decision Support
Always review the patient's clinical documentation thoroughly. When in doubt, choose the more specific code and ensure documentation supports it.
Key Information
Essential facts and insights aboutMetastatic Adenocarcinoma
Alternative codes to consider when ruling out similar conditions
Documentation & Coding Risks
Avoid these common issues when documenting Metastatic Adenocarcinoma.
Documenting 'metastatic cancer' without specifying sites
Impact
Clinical: Inadequate treatment planning., Regulatory: Non-compliance with coding standards., Financial: Potential claim denials.
Mitigation
Always specify primary and secondary sites.
Using C80.1 without confirming unknown primary
Impact
Reimbursement: May lead to claim denials or reduced reimbursement., Compliance: Non-compliance with coding guidelines., Data Quality: Inaccurate data on cancer epidemiology.
Mitigation
Ensure documentation explicitly states 'unknown primary'.
Use of unspecified codes
Impact
High risk of audit if C80.1 is overused.
Mitigation
Document primary site or confirm unknown status.